Latest news

On May 18-20, Nanologica took part of the Biotechgate Digital Partnering Conference. The purpose of the conference was to offer companies the possibility to continue business development and interact with partners, clients, licensees/licensors and suppliers. During the conference, several online meetings were held with various pharma companies, and the leads will be followed up during the coming months.

Styrelsens förslag – Beslut om emissionsbemyndigande, Nanologica AB Styrelsens förslag – Beslut om ändring av bolagsordningen, Nanologica AB Aktieägarens Flerie Invest AB förslag – Beslut om incitamentsprogram för styrelsen, Nanologica AB Styrelsens förslag – Beslut om incitamentsprogram för VD, ledning och övriga anställda, Nanologica AB    

At the PartneringAgainstCovid19 conference that Nanologica took part of last week, a few global players showed a great interest in Nanologica’s platform solutions. Encouraged by this, Nanologica has decided to take part of the upcoming Biotechgate Digital Partnering Conference on May 18-20. The purpose of the conference is to offer companies the possibility to continue business development and interact with partners, clients, licensees/licensors and suppliers. For Nanologica, these conferences mean good opportunities to expand the

The trademark NLAB Saga™ has now been approved in India and Russia. NLAB Saga™ is Nanologica’s product for preparative chromatography and has been developed for large scale purification of proteins and peptides, e.g. insulin. Comparison of NLAB Saga™ to competitors in terms of alkaline stability shows that NLAB Saga™ withstands the harsh experimental conditions used in insulin purification and performs consistently well – comparable with the market leader and well ahead of other competitors. NLAB

Nanologica deltar i ett seminarium på temat generika/biosimilarer och drug delivery teknologier anordnat av Redeye den 16 april. Nanologica kommer att presentera sin verksamhet och vad som gör det intressant att investera i bolaget. Moderatorer är Redeyes life science-analytiker Jakob Svensson och Niklas Elmhammer. Länk till eventet: Biosimilar/Drug Delivery Seminar – 16 april